UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ____)
PROVECTUS PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
74373F100
--------------------------------------------------------------------------------
(CUSIP Number)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|X| Rule 13d-1(c)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s)
Page 1 of 4 Pages
------------------- -------------------
CUSIP No. 74373F100 13G Page 2 of 4 Pages
------------------- -------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Alpha Capital Aktiengesellschaft
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,166,667 Common stock
--------------------------------------------------------------------------------
6. SHARED VOTING POWER
None
--------------------------------------------------------------------------------
7. SOLE DISPOSITIVE POWER
1,166,667 shares of Common Stock
--------------------------------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,166,667 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_|
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.8%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
------------------- -------------------
CUSIP No. 74373F100 13G Page 3 of 4 Pages
------------------- -------------------
ITEM 1 (a) NAME OF ISSUER:
Provectus Pharmaceuticals, Inc.
ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931
ITEM 2 (a) NAME OF PERSON FILING:
Alpha Capital Aktiengesellschaft
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein
ITEM 2 (c) CITIZENSHIP:
Liechtenstein
ITEM 2 (d) TITLE OF CLASS OF SECURITIES:
Common Stock, $.001 par value
ITEM 2 (e) CUSIP NUMBER:
74373F100
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B):
Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 1,166,667 Shares of Common Stock
(b) PERCENT OF CLASS: 5.8%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
1,166,667 Shares
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
1,166,667 Shares
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0 Shares
------------------- -------------------
CUSIP No. 74373F100 13G Page 4 of 4 Pages
------------------- -------------------
ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable
ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable
ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP
Not applicable
ITEM 9 NOTICE OF DISSOLUTION OF GROUP
Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 7, 2006
--------------------------------------
(Date)
/s/ Konrad Ackerman
--------------------------------------
(Signature)
Konrad Ackerman, Director
--------------------------------------
(Name/Title)